Skip to main content
SkinCited

Lactobacillus rhamnosus per Eczema (Atopic Dermatitis)

B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'skincited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u0026condition\u003Deczema\u002Datopic\u002Ddermatitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Meta-analyses found L. rhamnosus GG reduced the risk of atopic dermatitis by approximately 50% in high-risk infants and improved SCORAD scores in children with established eczema.

Key Study Findings

Review
Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG.
Dose: None vs: None Outcome: Diarrhea, colic, allergy, atopic dermatitis Effetto: None None

Popolazione: Pediatric patients

Randomized Controlled Trial
[Effectiveness and safety of probiotics in children on the basis of clinical trials].
Dose: None vs: None Outcome: diarrhea Effetto: None None

Popolazione: None

Key Statistics

20

Studi

3500

Partecipanti

Positive

B

Grado

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1-10 billion CFU/day
atopicdermatitis:
10 billion CFU/day L. rhamnosus GG

Limite massimo: Not established; generally well-tolerated at doses up to 100 billion CFU/day

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
None -- Positive --

Momento migliore per l'assunzione: Before or with meals; some studies suggest empty stomach

Safety & Side Effects

Effetti collaterali segnalati

  • Mild gas or bloating (temporary, during initial use)
  • Rare infections in severely immunocompromised individuals

Interazioni note

  • Immunosuppressants (theoretical concern — live bacteria)
  • Antibiotics (may reduce probiotic viability — separate by 2+ hours)

Livello di assunzione massimo tollerabile: Not established; generally well-tolerated at doses up to 100 billion CFU/day

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Lactobacillus rhamnosus help with Eczema (Atopic Dermatitis)?
Based on 20 studies with 3,500 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus may support Eczema (Atopic Dermatitis) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus should I take for Eczema (Atopic Dermatitis)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus?
Reported side effects may include Mild gas or bloating (temporary, during initial use), Rare infections in severely immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus and Eczema (Atopic Dermatitis)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 3,500 total participants. The overall direction of effect is positive.

Lactobacillus rhamnosus per altre condizioni

References

  1. [1] Christian Boggio Marzet et al.. Arch Argent Pediatr. 2022. Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG. doi:10.5546/aap.2022.eng.e1 PubMed
  2. [2] Ewa Kamińska. Med Wieku Rozwoj. 2012. [Effectiveness and safety of probiotics in children on the basis of clinical trials]. PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.